miR-106b promotes proliferation and invasion by targeting Capicua through MAPK signaling in renal carcinoma cancer

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. Urol Oncol. 2017;35(3):102–110. doi:10.1016/j.urolonc.2016.12.00228089416
   PubMed Web of Science ®Google Scholar
• Wu YY, Liu XY, Zhuo DX, Huang HB, Zhang FB, Liao SF. Decreased expression of TRPV1 in renal cell carcinoma: association with tumor Fuhrman grades and histopathological subtypes. Cancer Manag Res. 2018;10:1647–1655. doi:10.2147/CMAR.S16639029970964
   PubMedGoogle Scholar
• Lee HJ, Shin DH, Kim SY, et al. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis. Histopathology. 2018. doi:10.1111/his.13700
   Web of Science ®Google Scholar
• Chen D, Chen W, Xu Y, et al. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet. 2019;56(1):43–49. doi:10.1136/jmedgenet-2018-105454.
   Web of Science ®Google Scholar
• Yamada Y, Arai T, Kojima S, et al. Regulation of anti-tumor miR-144-5p targets oncogenes: direct regulation of syndecan-3 and its clinical significance. Cancer Sci. 2018. doi:10.1111/cas.13722
   Web of Science ®Google Scholar
• Lai Y, Quan J, Hu J, et al. miR-199b-5p serves as a tumor suppressor in renal cell carcinoma. Exp Ther Med. 2018;16(1):436–444. doi:10.3892/etm.2018.615129896270
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974. doi:10.1016/j.jconrel.2013.09.01524075926
   PubMed Web of Science ®Google Scholar
• Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkowicz A, Dulak J. MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem. 2011;401(7):2051–2061. doi:10.1007/s00216-011-5001-821544542
   PubMed Web of Science ®Google Scholar
• Wei X, Yu L, Kong X. miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5. Onco Targets Ther. 2018;11:2205–2216. doi:10.2147/OTT.S15636129713189
   PubMed Web of Science ®Google Scholar
• Liu E, Sun X, Li J, Zhang C. miR30a5p inhibits the proliferation, migration and invasion of melanoma cells by targeting SOX4. Mol Med Rep. 2018;18(2):2492–2498.doi:10.3892/mmr.2018.9166.
   Google Scholar
• Li M, Wang Y, Song Y, et al. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Oncol Rep. 2015;33(4):1571–1578. doi:10.3892/or.2015.379925682771
   PubMed Web of Science ®Google Scholar
• Yu S, Qin X, Chen T, Zhou L, Xu X, Feng J. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anticancer Drugs. 2017;28(8):852–860. doi:10.1097/CAD.000000000000052428723865
   PubMed Web of Science ®Google Scholar
• Yao YL, Wu XY, Wu JH, et al. Effects of microRNA-106 on proliferation of gastric cancer cell through regulating p21 and E2F5. Asian Pac J Cancer Prev. 2013;14(5):2839–2843.23803041
   PubMedGoogle Scholar
• Liu K, Jing Y, Zhang W, et al. Silencing miR-106b accelerates osteogenesis of mesenchymal stem cells and rescues against glucocorticoid-induced osteoporosis by targeting BMP2. Bone. 2017;97:130–138. doi:10.1016/j.bone.2017.01.01428108317
   PubMed Web of Science ®Google Scholar
• Lee CJ, Chan WI, Cheung M, et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol. 2002;106(1–2):151–156.
   PubMedGoogle Scholar
• Jimenez G, Guichet A, Ephrussi A, Casanova J. Relief of gene repression by torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev. 2000;14(2):224–231.10652276
   PubMed Web of Science ®Google Scholar
• Astigarraga S, Grossman R, Diaz-Delfin J, Caelles C, Paroush Z, Jimenez G. A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling. Embo J. 2007;26(3):668–677. doi:10.1038/sj.emboj.760153217255944
   PubMed Web of Science ®Google Scholar
• Fores M, Simon-Carrasco L, Ajuria L, et al. A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genet. 2017;13(3):e1006622. doi:10.1371/journal.pgen.100662228278156
   PubMed Web of Science ®Google Scholar
• Tan Q, Brunetti L, Rousseaux MWC, et al. Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma. Proc Natl Acad Sci U S A. 2018;115(7):E1511–E9. doi:10.1073/pnas.171645211529382756
   PubMed Web of Science ®Google Scholar
• Kim E, Kim D, Lee JS, et al. Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology. 2018;67(6):2287–2301. doi:10.1002/hep.2973829251790
   PubMed Web of Science ®Google Scholar
• Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006;15(13):2125–2137. doi:10.1093/hmg/ddl13616717057
   PubMed Web of Science ®Google Scholar
• Lam YC, Bowman AB, Jafar-Nejad P, et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell. 2006;127(7):1335–1347. doi:10.1016/j.cell.2006.11.03817190598
   PubMed Web of Science ®Google Scholar
• Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 2005;83(1):1–14. doi:10.1139/o04-12115746962
   PubMedGoogle Scholar
• Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995;55(18):4182–4187.7664295
   PubMed Web of Science ®Google Scholar
• Kotlarek M, Kubiak A, Jazdzewski K, Wojcicka A. MicroRNA analysis using the quantitative real-time PCR reaction. Methods Mol Biol. 2018;1823:69–85. doi:10.1007/978-1-4939-8624-8_729959675
   PubMedGoogle Scholar
• Yang H, Song E, Shen G, et al. Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents. Onco Targets Ther. 2017;10:579–590. doi:10.2147/OTT.S11579128203091
   PubMed Web of Science ®Google Scholar
• Kaur G, Li CG, Chantry A, Stayner C, Horsfield J, Eccles MR. SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-beta1) signalling in renal cell carcinoma. Oncotarget. 2018;9(42):26852–26867. doi:10.18632/oncotarget.2551629928489
   PubMedGoogle Scholar
• Zhao S, Wang Y, Luo M, Cui W, Zhou X, Miao L. Long noncoding rna small nucleolar rna host gene 1 (SNHG1) promotes renal cell carcinoma progression and metastasis by negatively regulating miR-137. Med Sci Monit. 2018;Jun(24):3824–3831. doi:10.12659/MSM.910866
   Google Scholar
• Chebib I, Jo VY. Round cell sarcoma with CIC-DUX4 gene fusion: discussion of the distinctive cytomorphologic, immunohistochemical, and molecular features in the differential diagnosis of round cell tumors. Cancer Cytopathol. 2016;124(5):350–361. doi:10.1002/cncy.2168526800124
   PubMed Web of Science ®Google Scholar
• Yang R, Chen LH, Hansen LJ, et al. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Res. 2017;77(22):6097–6108. doi:10.1158/0008-5472.CAN-17-101828939681
   PubMed Web of Science ®Google Scholar
• Zhang J, Du Y, Zhang X, Li M, Li X. Downregulation of BANCR promotes aggressiveness in papillary thyroid cancer via the MAPK and PI3K Pathways. J Cancer. 2018;9(7):1318–1328. doi:10.7150/jca.2015029675113
   PubMed Web of Science ®Google Scholar
• Carabia J, Carpio C, Abrisqueta P, et al. Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Sci Rep. 2017;7(1):12262. doi:10.1038/s41598-017-12135-728947822
   PubMedGoogle Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205. doi:10.1016/j.ctrv.2007.12.00118313224
   PubMed Web of Science ®Google Scholar
• Pal SK, Nelson RA, Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One. 2013;8(5):e63341. doi:10.1371/journal.pone.006334123658823
   PubMed Web of Science ®Google Scholar
• Wei S, Bing Z, Yao Y, Master SR, Gupta P. Higher expression of mir-182 in cytology specimens of high-grade urothelial cell carcinoma: a potential diagnostic marker. Acta Cytol. 2015;59(1):109–112. doi:10.1159/00037150725676538
   PubMedGoogle Scholar
• Khella HW, Scorilas A, Mozes R, et al. Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma. Am J Pathol. 2015;185(3):693–703. doi:10.1016/j.ajpath.2014.11.01725572155
   PubMed Web of Science ®Google Scholar
• Liu L, Liu S, Duan Q, et al. MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3. Am J Transl Res. 2017;9(5):2394–2402.28559989
   PubMed Web of Science ®Google Scholar
• Perske C, Lahat N, Sheffy Levin S, Bitterman H, Hemmerlein B, Rahat MA. Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. Am J Pathol. 2010;177(4):2046–2054. doi:10.2353/ajpath.2010.09111120709800
   PubMed Web of Science ®Google Scholar
• Lian JH, Wang WH, Wang JQ, Zhang YH, Li Y. MicroRNA-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/Akt signaling pathway. Asian Pac J Cancer Prev. 2013;14(9):5017–5021.24175769
   PubMedGoogle Scholar
• Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19(7):1292–1300.23092349
   PubMed Web of Science ®Google Scholar
• He QY, Wang GC, Zhang H, et al. miR-106a-5p suppresses the proliferation, migration, and invasion of osteosarcoma cells by targeting HMGA2. DNA Cell Biol. 2016;35(9):506–520. doi:10.1089/dna.2015.312127383537
   PubMed Web of Science ®Google Scholar
• Yu L, Xiang L, Feng J, et al. miRNA-21 and miRNA-223 expression signature as a predictor for lymph node metastasis, distant metastasis and survival in kidney renal clear cell carcinoma. J Cancer. 2018;9(20):3651–3659.30405833
   PubMed Web of Science ®Google Scholar
• Lin C, Li Z, Chen P, et al. Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma. Life Sci. 2018;15(209):481–489. doi:10.1016/j.lfs.2018.08.044
   Google Scholar
• Pan X, Li Z, Zhao L, et al. microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis. Oncol Rep. 2018;40(5):3092–3101. doi:10.3892/or.2018.664930132566
   PubMed Web of Science ®Google Scholar
• Simon-Carrasco L, Jimenez G, Barbacid M, Drosten M. The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle. 2018;17(6):702–711. doi:10.1080/15384101.2018.145002929578365
   PubMed Web of Science ®Google Scholar
• Hu Y, Li K, Asaduzzaman M, et al. MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep. 2016;35(2):1170–1178. doi:10.3892/or.2015.441226573761
   PubMed Web of Science ®Google Scholar
• Mastropasqua F, Marzano F, Valletti A, et al. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Mol Cancer. 2017;16(1):67. doi:10.1186/s12943-017-0634-728327152
   PubMedGoogle Scholar
• Koster R, Di Pietro A, Timmer-Bosscha H, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120(10):3594–3605. doi:10.1172/JCI4193920811155
   PubMed Web of Science ®Google Scholar
• Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci. 2018;22(15):4879–4887. doi:10.26355/eurrev_201808_1562430070323
   PubMed Web of Science ®Google Scholar
• Chen Q, Li KT, Tian S, et al. Photodynamic therapy mediated by aloe-emodin inhibited angiogenesis and cell metastasis through activating MAPK signaling pathway on HUVECs. Technol Cancer Res Treat. 2018;Jan(17):1533033818785512.
   Google Scholar
• Sheng L, Tang T, Liu Y, et al. Inducible HSP70 antagonizes cisplatininduced cell apoptosis through inhibition of the MAPK signaling pathway in HGC27 cells. Int J Mol Med. 2018;42(4):2089–2097. doi:10.3892/ijmm.2018.378930066840
   PubMed Web of Science ®Google Scholar
• Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–418. doi:10.1016/j.apsb.2015.07.00526579471
   PubMed Web of Science ®Google Scholar
• De Lisi D, De Giorgi U, Lolli C, et al. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol. 2018;14(4):461–467. doi:10.1080/17425255.2018.145582629557694
   PubMed Web of Science ®Google Scholar
• Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016;11:23–36. doi:10.2147/CE.S9868727621699
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281. doi:10.1056/NEJMoa06683817538086
   PubMed Web of Science ®Google Scholar
• Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121(2):179–193. doi:10.1016/j.cell.2005.02.03115851026
   PubMed Web of Science ®Google Scholar
• Ruicci KM, Pinto N, Khan MI, et al. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. Oral Oncol. 2018;84:95–103. doi:10.1016/j.oraloncology.2018.07.01030115483
   PubMed Web of Science ®Google Scholar